First personal eyelid massager launched in the UK

Ophthalmologists develop device to treat MGD

31 Aug 2015 by Robina Moss

A device developed by two ophthalmologists for the treatment of Meibomian gland dysfunction (MGD) has been launched in the UK.

The device, Eyepeace, is said to be the first personal eyelid massager designed to unblock the meibomian gland, and prevent and treat MGD.

It was launched in Northern Ireland earlier this month and is now available in the UK, with global partnerships said to be “coming soon.”

The Eyepeace is a CE-marked class 1 medical device and is made from medical grade implantable silicone, which is safe for the skin.

An important step in treating and preventing MGD is massaging the eyelids in a vertical motion to unblock the glands. Developing a regular daily routine of eyelid massage and hygiene is essential in its treatment, as it tends to recur and rarely disappears completely, the ophthalmologists explained.

Eyepeace co-inventors Professors Johnny Moore and Anant Sharma, who are consultant ophthalmologists in the field of ocular surface disease and dry eyes, developed the device with Cranfield University design engineers in a bid to address the need for hygienic and reproducible vertical eyelid massage.

Professor Moore, visiting professor at the University of Ulster, said: “The Eyepeace is a unique device that we have created in response to an obvious patient need. It is a world first and will enable sufferers to avoid the painful symptoms of dry eyes by unblocking the glands and therefore facilitating the self-lubrication of the eyes, without the need for eye drops.”

Professor Sharma, visiting professor at Cranfield University, added: “Our easy to use, cost effective device provides a natural therapy for MGD. The device will help optometrists to train patients to correctly massage the glands effectively and therefore lead to better compliance.”

For more information, visit the Eyepeace website. 


Your comments

You must be logged in to join the discussion. Log in

Comments (0)

Report a comment
Close modal